Evidence map›Paper›PMID 38531508›Full record

ArticleJournal of substance use and addiction treatment2024

Patient and provider medication preferences affect treatment outcomes among adolescents and young adults with opioid use disorder.

Laura B Monico, Jesse B Fletcher, Tyler Ross, Robert P Schwartz, Marc J Fishman, Jan Gryczynski, Shannon Gwin Mitchell

Open access · greenAbstract read
In one paragraph

Article in Journal of substance use and addiction treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. The Impact of Antihypertensive De-escalation: A Secondary Analysis of Systolic Blood Pressure Intervention Trial (SPRINT).High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Laura B MonicoFriends Research Institute Inc, United States of America. Electronic address: lmonico@friendsresearch.org.
Jesse B FletcherFriends Research Institute Inc, United States of America.
Tyler RossMemorial University of Newfoundland, United States of America.
Robert P SchwartzFriends Research Institute Inc, United States of America.
Marc J FishmanMaryland Treatment Centers Inc, United States of America.
Jan GryczynskiFriends Research Institute Inc, United States of America.
Shannon Gwin MitchellFriends Research Institute Inc, United States of America.
Friends Research Institute · US

Funding

Health Services Research: Extended Release Naltrexone for Opioid-Dependent YouthR01DA033391 · NIDA · FRIENDS RESEARCH INSTITUTE, INC. · PI MITCHELL, SHANNON GWIN · 2013 to 2018
$3.3M
NIDA NIH HHS R01 DA033391
6 · The paper itself

Abstract

backgroundThe opioid epidemic in the United States has not spared youth or young adults, as evidenced by a six-fold increase in opioid use disorder (OUD) diagnoses in the last two decades. Given this dramatic rise, a call for greater uptake and accessibility of medications for opioid use disorder (MOUDs) among youth and young adults has ensued, resulting in an increasing number of MOUD treatment pathways for this vulnerable population.

methodsThis secondary data analysis seeks to characterize patient and provider preferences for MOUD treatment pathways, and test for associations between baseline MOUD treatment preferences and opioid use and treatment adherence outcomes. Participants included 288 youth and young adults (age 15-21 years), recruited from a residential treatment program in Maryland. The study assessed patient preferences at baseline (n = 253) and provider preferences at patient treatment discharge (n = 224). Mixed-effects negative binomial regression models were conducted for opioid use outcomes, and logistic regressions were conducted for treatment adherence outcomes.

resultsResults indicate that congruence of treatment with patients' (Incidence Rate Ratio [IRR] = 0.65) and providers' (IRR = 0.66) preferences was significantly associated with reduced self-reported days of opioid use in the past 90 days, but only for patients receiving extended-release naltrexone (XR-NTX). Results also indicated that patients were less likely to switch medication treatment pathways (e.g., from XR-NTX to buprenorphine, or vice versa) during follow-up if they received their preferred treatment at baseline, a finding which held true for both XR-NTX (Odds Ratio [OR] = 0.32) and buprenorphine (OR = 0.22).

conclusionsReceipt of MOUD congruent with patient and provider preferences was associated with reduced opioid use and greater treatment adherence in this sample of youth and young adults with OUD.

Indexed as

Opioid-Related DisordersPatient PreferenceAdolescentAdultBuprenorphineDrug MonitoringFemaleHumansMaleMarylandMedication AdherenceNaltrexoneOpiate Substitution TreatmentResidential TreatmentTreatment OutcomeYoung AdultBuprenorphineNaltrexoneAdolescentBuprenorphineExtended-release naltrexone (XR-NTX)MOUDOpioid use disorderYoung adult

Identifiers

PMID38531508
PMCPMC11163270
OpenAlexW4393130182

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.